Template-type: ReDIF-Paper 1.0 Author-Name: Hagedoorn, John Author-Email: j.hagedoorn@maastrichtuniversity.nl Author-Workplace-Name: UNU-MERIT, and Maastricht University Author-Name: Wang, Ning Author-Email: n.wang@maastrichtuniversity.nl Author-Workplace-Name: Maastricht University Title: Is there complementarity or substitutability between internal and external R&D strategies? Abstract: The mixed picture of extant research on the relationship between internal and external R&D prompts us to ask such a question: under what conditions is there complementarity or substitutability between different R&D strategies? The goal of this paper is to contribute to the empirical literature by advancing and testing the contingency of the relationship between internal and external R&D strategies in shaping firms‘ innovative output. Using a panel sample of incumbent pharmaceutical firms covering the period 1986-2000, our empirical analysis suggests that the level of in-house R&D investments, which is characterized by decreasing marginal returns, is a contingency variable that critically influences the nature of the link between internal and external R&D strategies. In particular, internal R&D and external R&D, through either R&D alliances or R&D acquisitions, turn out to be complementary innovation activities at higher levels of in-house R&D investments, whereas at lower levels of in-house R&D efforts internal and external R&D are substitutive strategic options. These findings are robust to alternative specifications and estimation techniques, including a dynamic perspective on firm innovative performance. Classification-JEL: O32, L24 Keywords: Complementarity, Substitutability, Internal R&D, External R&D, Innovative Output, Pharmaceutical Industry, Biotechnology Series: UNU-MERIT Working Papers Creation-Date: 2010 Number: 005 File-URL: http://www.merit.unu.edu/publications/wppdf/2010/wp2010-005.pdf File-Format: application/pdf File-Size: 275 Kb Handle: RePEc:unm:unumer:2010005